School project · Delayed data · Not financial adviceTerms
SingularityViewAll companies

Stock research

Zentalis Pharmaceuticals, Inc. ZNTL

Healthcare · Biotechnology

$2.52last close 2026-10-12 · market cap $247.27M · delayed data

Trailing returns

1M-28.21%
3M-48.36%
6M-61.88%
1Y+50.00%
5Y-96.81%

Basis: Adjusted daily closes.

What it does

Zentalis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers in the United States. It develops azenosertib, which is in a Phase 3 clinical trial for the treatment of ovarian cancer and other tumor types.

Open ZNTL in the live terminal →

Valuation, cost of capital, SEC filings, ownership and more, with the source named on every figure.

Post on XLinkedInEmail

Where these figures come from

Delayed data. Not financial advice. Figures are read from the sources above at the dates shown; nothing here is a recommendation. Disclosures · All companies